Sign in Subscribe

Archive

A collection of 715 issues

Latest

AZUR-4 trial testing immunotherapy before surgery in MSS colon cancer

Skip to content The CRC Digest ◆ TRIAL DATA AZUR-4 trial testing immunotherapy before surgery in MSS colon cancer — Clinical Colorectal Cancer AZUR-4 is a phase 2, open-label, randomized study comparing neoadjuvant (before surgery) dostarlimab plus CAPEOX chemotherapy versus CAPEOX alone in previously untreated stage III or high-risk stage II mismatch

Phase 2 trial tests fruquintinib plus chemotherapy in RAS-mutant CRC

Skip to content The CRC Digest ◆ TRIAL DATA Phase 2 trial tests fruquintinib plus chemotherapy in RAS-mutant CRC — Journal of Clinical Oncology A multicenter, open-label phase 2 study evaluated fruquintinib (a targeted therapy) combined with FOLFIRI or mFOLFOX6 chemotherapy as second-line treatment for patients with RAS-mutant metastatic colorectal cancer. RAS

Prior anti-EGFR therapy affects HER2-targeted treatment outcomes

Skip to content The CRC Digest ▸ TREATMENT Prior anti-EGFR therapy affects HER2-targeted treatment outcomes — ESMO Open An integrated analysis of the TRIUMPH and MyPathway studies examined how prior treatment with anti-EGFR (epidermal growth factor receptor) therapy affects the effectiveness of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer. The study

Blood test after surgery predicts recurrence in metastatic colorectal cancer

Skip to content The CRC Digest ▪ SCREENING Blood test after surgery predicts recurrence in metastatic colorectal cancer — Cancer Treatment Reviews A systematic review and meta-analysis found that detecting circulating tumor DNA (ctDNA) after surgery for metastatic colorectal cancer strongly predicts which patients will experience recurrence. This molecular residual disease (MRD)

Dual immunotherapy shows durable benefit in MSI-H colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Dual immunotherapy shows durable benefit in MSI-H colorectal cancer — Journal of Clinical Oncology Long-term follow-up from the CheckMate 8HW phase 3 trial examined outcomes in patients with MSI-H/dMMR (microsatellite instability-high/mismatch repair-deficient) metastatic colorectal cancer treated with nivolumab plus ipilimumab versus

Liquid biopsy predicts which KRAS G12C patients will benefit from targeted therapy

Skip to content The CRC Digest ◆ TRIAL DATA Liquid biopsy predicts which KRAS G12C patients will benefit from targeted therapy — Journal of Clinical Oncology . This blood-based test could help doctors identify which patients are responding to treatment without waiting for scans. What this means If you have a KRAS G12C

CRC Research Update — May 29, 2026

Today's colorectal cancer research highlights

Baseline ctDNA profiling informs HER2-targeted therapy outcomes

Skip to content The CRC Digest Baseline ctDNA profiling informs HER2-targeted therapy outcomes TRIUMPH/MyPathway analysis shows baseline circulating tumor DNA and prior anti-EGFR therapy affect pertuzumab plus trastuzumab efficacy in HER2-amplified metastatic colorectal cancer. (ESMO Open) This content is informational only and does not constitute medical advice. Always consult

ctDNA clearance as early biomarker in KRAS G12C colorectal cancer

Skip to content The CRC Digest ctDNA clearance as early biomarker in KRAS G12C colorectal cancer Phase 3 CodeBreaK 300 results link circulating tumor DNA clearance to efficacy and prognosis with sotorasib plus panitumumab. (JCO) This content is informational only and does not constitute medical advice. Always consult your oncologist

CRC Research Finding

Skip to content The CRC Digest ● American Cancer Society updates colorectal cancer screening guideline to include new molecular tests The 2026 guideline update reaffirms screening starting at age 45 and adds newly FDA-approved molecular-based tests—a multitarget stool RNA test, a next-generation mt-sDNA test, and a blood-based cell-free DNA assay—